3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Neoplasms
2
Lymphoma, Non-Hodgkin
2
Carcinoma, Renal Cell
2
Zollinger-Ellison Syndrome
1
Uterine Cervical Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Philadelphia Chromosome
1
Melanoma
1
Lymphoproliferative Disorders
1
Lymphomatoid Granulomatosis
1
Lymphoma, Follicular
1
Lymphoma
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Gastrointestinal Cancer Metastatic
1
Epstein-Barr Virus Infections
1
Carcinoma, Hepatocellular
1
Blast Crisis
1
Adenoma, Islet Cell
1
Interventions
Imatinib Mesylate
8
Dasatinib
4
Vincristine
3
Methotrexate
3
Dexamethasone
3
Cytarabine
3
peginterferon alfa-2a
2
Prednisone
2
Daunorubicin
2
Cyclophosphamide
2
venetoclax
1
ponatinib
1
olverembatinib
1
flumatinib
1
bosutinib
1
blinatumomab
1
Prednisolone
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Mitoxantrone
1
Mercaptopurine
1
Interferons
1
Inotuzumab Ozogamicin
1
Etoposide
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Philadelphia Chromosome
×
Interferons
×
Clear all
NCT00763763
2011-10-05
AFR07
Assistance Publique - Hôpitaux de Paris
Phase 2
Completed
55 enrolled